Launch of Apex Laser Series, the World’s First and Only High-Powered Multi-Wavelength Laser for Photobiomodulation

Launch of Apex Laser Series is the newest addition to the premium Aspen Laser family, positioning it ahead of the market as a flagship solution in photobiomodulation (laser therapy) reports Aspen Laser Systems.

The Apex Tri-Wave Laser model is the world’s first and only therapy laser that features three therapeutic wavelengths: 810nm, 980nm and 1064nm, each with the capability of operating at a max power of 15 watts and a combined total output of 45 watts.

With this new product launch, Aspen Laser introduces the 1064nm wavelength to the US market. The 1064nm wavelength is a longer wavelength that can penetrate deeper into tissue. Clinical studies indicate that it has the least dispersion within biological tissues due to its decreased melanin absorption. The result is deep activation of metabolic processes vital for all cellular activities.

The Apex Laser Series allows healthcare practitioners a new and effective clinical tool to deliver optimal outcomes. This new model combines exclusive high average power PowerDose diodes and advanced Wavelength MultiPlexer Technology to provide the broadest range and selections of therapeutic wavelengths. In addition to the Apex Tri-Wave 45 watt model, the Apex Laser Series includes a Dual-Wave Laser model option featuring 60 watts of total output with 30 watts each of 810nm and 1064nm (or 980nm) wavelengths. The Apex Dual-Wave Laser model is also the only one of its kind in the world.

“The Apex Laser Series is surpassing the results that we originally planned for,” said Charles Vorwaller, CEO of Aspen Laser Systems, LLC. “This product has been in research and development for the past two years, and because of the broad range of power, wavelengths and operating mode choices, it is a wonderful support for our Patient Response Driven Clinical Protocols. This means a healthcare professional will have significantly better outcomes and physiological effects that include increased circulation, reduced inflammation, pain reduction and enhanced tissue healing. The Apex Laser Series is a great addition for any healthcare professional, whether experienced or just starting out with photobiomodulation.”

Photobiomodulation is a non-invasive and painless treatment used to treat pain and inflammation from conditions such as arthritis, tendonitis, and acute joint or muscle injuries, and the treatment can be applied to both humans and animals. Instead of just treating symptoms that may provide temporary benefits, photobiomodulation is a superior treatment option because it provides energy to cells that trigger a chemical response resulting in the body to heal itself.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version